膀胱癌淋巴结转移的危险因素分析及临床意义探讨
Risk Factor Analysis and Clinical Significance Discussion of Lymph Node Metastasis in Bladder Cancer
DOI: 10.12677/ACM.2023.13112400, PDF,   
作者: 周星宇, 侯亚坤:新疆医科大学第一临床医学院,新疆 乌鲁木齐;木拉提·热夏提, 拜合提亚·阿扎提, 王玉杰, 王文光*:新疆医科大学第一附属医院泌尿中心,新疆 乌鲁木齐
关键词: 膀胱癌淋巴结转移危险因素Bladder Cancer Lymph Node Metastasis Risk Factors
摘要: 目的:探讨膀胱癌淋巴结转移的相关危险因素。方法:收集我院2008年1月~2021年8月收治的172例膀胱癌根治术患者临床资料,分析探讨淋巴结转移的影响因素。结果:膀胱癌患者淋巴结转移情况仅在电切标本浸润程度、病理标本浸润程度、是否血管淋巴浸润方面有显著差异,P < 0.05。多因素回归分析显示淋巴结转移与两项因素有关,电切病理标本浸润至肌层患者发生淋巴结转移的可能性是未浸润至肌层患者的5.619倍(P < 0.05),发生血管淋巴浸润的患者淋巴结转移的可能性是未发生的7.995倍(P < 0.05)。结论:电切病理标本浸润至肌层以及发生血管淋巴浸润会显著增加淋巴结转移可能。采取综合治疗措施以及积极的态度来治疗有以上危险因素的患者至关重要。
Abstract: Objective: To investigate the risk factors of lymph node metastasis in bladder cancer. Methods: The clinical data of 172 patients with bladder cancer who underwent radical surgery in our hospital from January 2008 to August 2021 were collected, and the influencing factors of lymph node me-tastasis were analyzed. Results: The lymph node metastasis of bladder cancer patients was signifi-cantly different only in the degree of invasion of resected specimens, the degree of invasion of pathological specimens, and whether there was vascular lymph infiltration (P < 0.05). Multivariate regression analysis showed that lymph node metastasis was related to two factors. Patients with pathological specimen infiltration into the muscle layer were 5.619 times more likely to have lymph node metastasis than those without infiltration into the muscle layer (P < 0.05), and patients with vascular lymphatic infiltration were 7.995 times more likely to have lymph node metastasis than those without infiltration (P < 0.05). Conclusion: The infiltration of pathological specimens into the muscle layer and the occurrence of vascular lymphatic infiltration significantly increase the possi-bility of lymph node metastasis. It is crucial to adopt comprehensive treatment measures and a positive attitude to treat patients with the above risk factors.
文章引用:周星宇, 侯亚坤, 木拉提·热夏提, 拜合提亚·阿扎提, 王玉杰, 王文光. 膀胱癌淋巴结转移的危险因素分析及临床意义探讨[J]. 临床医学进展, 2023, 13(11): 17123-17128. https://doi.org/10.12677/ACM.2023.13112400

参考文献

[1] Zheng, R.S., Zhang, S.W., Zeng, H.M., et al. (2022) Cancer Incidence and Motality in China, 2016. Journal of the Na-tional Cancer Center, 2, 1-9.
[2] Haupt, S., Caramia, F., Klein, S.L., Rubin, J.B. and Haupt, Y. (2021) Sex Disparities Matter in Cancer Development and Therapy. Nature Reviews Cancer, 21, 393-407. [Google Scholar] [CrossRef] [PubMed]
[3] 徐源佑, 张永辉, 丁璐璐, 等. 1972~2016年江苏省启东市膀胱癌生存率长期趋势分析[J]. 中国肿瘤, 2022, 31(9): 710-715.
[4] Moran, G.W., Li, G., Robins, D.J., et al. (2017) Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder Cancer. Bladder Cancer, 3, 245-258. [Google Scholar] [CrossRef
[5] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[6] 王丽鹃, 刘自晓, 胡伟, 等. 膀胱癌淋巴结转移术前评估研究进展[J]. 中国医学科学院学报, 2023, 45(3): 464-470.
[7] Youssef, R.F. and Raj, G.V. (2011) Lymphadenectomy in Man-agement of Invasive Bladder Cancer. International Journal of Surgical Oncology, 2011, Article ID: 758189. [Google Scholar] [CrossRef] [PubMed]
[8] Shariat, S.F., Ehdaie, B., Rink, M., et al. (2012) Clinical Nodal Staging Scores for Bladder Cancer: Aproposal for Preoperative Risk Assessment. European Urology, 61, 237-242. [Google Scholar] [CrossRef] [PubMed]
[9] 陈双. 膀胱癌转移淋巴结最大径的预后意义及在TNM分期中的价值[D]: [硕士学位论文]. 广州: 南方医科大学, 2019.
[10] 黄翻. 膀胱癌淋巴结转移与其分期分级相关性的回顾性分析[D]: [硕士学位论文]. 昆明: 昆明医科大学, 2020.
[11] 孙其鹏, 狄金明, 湛海伦, 等. 根治性膀胱切除术前淋巴结转移预测的相关指标分析[J]. 中华腔镜泌尿外科杂志(电子版), 2014, 8(5): 334-337.
[12] Stein, J.P., Cai, J., Groshen, S., et al. (2003) Risk Factors for Patients with Pelviclymph Node Metastases Following Radical Cystectomy with En Blocpelvic Lymphadenectomy: Concept of Lymph Node Density. Journal of Urology, 170, 35-41. [Google Scholar] [CrossRef] [PubMed]
[13] 申克辉, 虞巍, 张凯, 等. 不同病理分级分期膀胱癌淋巴结转移的分布状态: 208例根治性膀胱切除连续病例分析[J]. 中华泌尿外科杂志, 2010(2): 99-103.
[14] Her-mans, T.J.N., Voskuilen, C.S., Deelen, M., et al. (2019) Superior Efficacy of Neoadjuvant Chemotherapy and Radical Cystectomy in cT3-4aN0M0 Compared to cT2N0M0 Bladder Cancer. International Journal of Cancer, 144, 1453-1459. [Google Scholar] [CrossRef] [PubMed]
[15] Massari, F., Santoni, M., di Nunno, V., et al. (2018) Adjuvant and Neoad-juvant Approaches for Urothelial Cancer: Updated Indications and Controversies. Cancer Treatment Reviews, 68, 80-85. [Google Scholar] [CrossRef] [PubMed]
[16] 李慧, 姜行康, 马宝杰, 等. 淋巴血管侵犯在电切术后高级别T_1期膀胱癌中的临床病理意义[J]. 中华泌尿外科杂志, 2015, 36(2): 126-130.
[17] Tilki, D., Shariat, S.F., Lotan, Y., et al. (2012) Lymphovascular Invasion is Independently Associated with Bladder Cancer Recurrence and Survival in Patients with Final Stage T1 Disease and Negative Lymph Nodes after Radical Cystectomy. BJU International, 111, 1215-1221. [Google Scholar] [CrossRef
[18] Witjes, J.A., Bruins, H.M.M., Cathomas, R.L., et al. (2020) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 79, 82-104. [Google Scholar] [CrossRef] [PubMed]
[19] 林明亮, 李科威, 王启开, 等. 肌层浸润性膀胱癌保留膀胱综合治疗的疗效分析[J]. 潍坊医学院学报, 2023, 45(5): 362-365.
[20] 周述银, 周健, 张茂. 长非编码RNA PCAT7对肌层浸润性膀胱癌发病的影响[J]. 南昌大学学报(医学版), 2019, 59(5): 21-23+51.
[21] 谢伟槟, 刘皓, 孔坚秋, 等. 膀胱癌盆腔淋巴结转移的规律及影响因素分析[J]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(6): 397-401.
[22] 郝瀚, 吴鑫, 郑卫, 等. 膀胱尿路上皮癌淋巴结转移特点: 单中心522例膀胱根治性切除病例回顾[J]. 北京大学学报(医学版), 2014, 46(4): 524-527.
[23] Gschwend, J.E., Heck, M.M., Lehmann, J., et al. (2016) Limited versus Extended Pelvic Lymphadenectomy in Patients with Bladder Cancer Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial (LEA AUO AB 25/02). Journal of Clinical Oncology, 34, 4503-4503. [Google Scholar] [CrossRef